Arrowhead Pharmaceuticals, Inc.
ARWR
NASDAQ·Healthcare·Biotechnology·Mkt cap $12.2B
$86.34
▼ -0.17%
P/E
-33.60
Mkt Cap
$12.2B
52-Wk Range
$27.10–$95.49
52-Week Range
$27.10 - $95.49
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 217.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary RNA interference (RNAi) platform technology for genetic silencing
- Strategic partnerships with Janssen Pharmaceuticals and Takeda for co-development and commercialization
- Diversified pipeline targeting multiple therapeutic areas with high unmet medical needs
- Focus on genetically validated targets reducing development risk
Bear Case
1 risk
- Average volatility.
Growth
Revenue decline expected
Advancement of clinical-stage candidates through Phase 2 and Phase 3 trials
Value
Trading at 0.0x Biotech & Therapeutics peers — a discount despite the growth profile.
Momentum
Strong
+16.9% over 3m
Quality
Excellent
Emerging growth company (9% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying ARWR right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 24, 2026
AUG 4, 2026
Reported EPS of -$1.36 vs -$1.28 consensus (-6.3% surprise). Revenue of $75.3M vs $44.2M expected (+70.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-6.3%
Revenue trend · last 8Q
—
+47%
-30%
—
—
+987%
+10461%
+171%
Q3 24
Q4 24
Q1 24
Q2 25
Q3 25
Q4 25
Q1 25
Q3 26
$0
$23.6M
$2.5M
$542.7M
$27.8M
$256.5M
$264.0M
$75.3M
Margins · last 8Q
Gross
0.0%
Operating
—
Profit
-258.2%
Wall Street consensus
6 analysts · 83% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
83%
Hold
17%
Sell
0%
Median Price Target
—
Latest: RBC Capital · Aug 31, 2026
vs Industry
How ARWR stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related